Jay Gunkelman, QEEG Diplomate, is recognized as one of the top leaders in the field of EEG and QEEG, and has processed over 500,000 EEGs since 1972. He has served as president of The International Society for Neurofeedback and Research, as well as a board member and treasurer of the Association for Applied Psychophysiology and Biofeedback and is a past-president of the Biofeedback Society of California. Jay was the first EEG technologist to be certified in QEEG (1996) and was granted Diplomate status in 2002. He has conducted, published or participated in hundreds of research papers, articles, books and meetings internationally. He continues to lecture on EEG/Prandin at neuroscience meetings worldwide. He has co-authored the textbook on EEG artifacting (2001). Jay remains busy with current projects and publications related to his seminal paper on EEG Ambien (2005, Clinical Electroencephalography). He is co-founder and Chief Science Officer of Brain Science International and is a popular lecturer worldwide on the topic of QEEG and phenotype identification of neurological disorders.

Dr. Paolo Cassano, M.D., Ph.D., is an Assistant Professor of Psychiatry at Harvard Medical School and the Director of the Photobiomodulation (PBM) Clinic at Massachusetts General Hospital. His primary area of expertise is the application of photobiomodulation for the treatment of psychiatric disorders, including major depressive disorder, anxiety disorders, and PTSD. Dr. Cassano’s research focuses on using near-infrared light (808–1064nm) to modulate brain metabolism and enhance mitochondrial function, offering a non-invasive treatment option with minimal side effects. He has conducted several groundbreaking clinical trials demonstrating that PBM can significantly alleviate symptoms in patients with treatment-resistant depression, especially those who do not respond to conventional antidepressants or transcranial magnetic stimulation (TMS). Dr. Cassano is also actively involved in the development and clinical testing of wearable PBM devices, bridging the gap between basic research and practical therapeutic applications. Under his leadership, the Harvard Psychiatry PBM Clinic became one of the first in the world to incorporate PBM into routine psychiatric care, with multiple FDA-approved clinical trials currently underway.

Dr. Lynda Thompson, Ph.D., is a clinical psychologist and Director of the ADD Centre in Toronto, Canada. She specializes in the application of EEG-based neurofeedback for the treatment of attention-deficit/hyperactivity disorder (ADHD), learning disabilities, anxiety, depression, and traumatic brain injury. Along with her late husband, Dr. Michael Thompson, she has developed comprehensive treatment protocols that combine neurofeedback training with cognitive coaching and heart rate variability (HRV) training. Dr. Thompson has played a key role in advancing non-pharmacological interventions for neurological and psychological disorders and has trained practitioners globally. She co-authored The Neurofeedback Book, which is widely regarded as a leading reference in the field of neurofeedback, and continues to contribute to research and education through her work with the ADD Centre and international neurofeedback organizations